Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study - Wikidata - awgldk - TriplyDB

Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study

Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study

http://www.wikidata.org/entity/Q35107521

about

Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms Cilostazol Modulates Autophagic Degradation of β-Amyloid Peptide via SIRT1-Coupled LKB1/AMPKα Signaling in Neuronal Cells Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion.Relationship between dietary pattern and cognitive function in elderly patients with type 2 diabetes mellitus.A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol.Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction.Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier.Influence of Low-Dose Aspirin on Cerebral Amyloid Angiopathy in Mice.Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.

P2860

Q27001177-438882A1-5204-4E28-94E1-83C8AB5F6EB1 Q28553396-1F922BE2-A3F7-4111-8F65-0E8CE9A671ED Q28828290-3B35EB76-9854-4D93-A48B-F87EA7D4F576 Q29994589-19BB150A-52B2-4E98-A7F5-A6FC202B1A2B Q34286389-842A7262-3639-4830-91AF-855EABD6E0CF Q34368970-199AD75F-0FB1-4FD2-8944-2C0B4D9F40A8 Q36288900-A03E487F-820C-4C2C-9AA7-AB4A1A6F613C Q38643963-14D8EB25-2FD5-48DA-AF52-E2BE440BD780 Q41025659-49B90873-751E-40BD-85D6-BD99CC65C38C Q41723747-0BED8BEA-47BE-4F50-BBC9-FA591612F786 Q42656245-D5AADB78-1C27-4CDF-B2D3-6CA4B4A46308 Q45305673-BA9EAEDE-7369-4EEA-9518-E98FAFE8ABF5 Q48043052-F8F4944F-64CB-487E-9259-790BEEEFF8CF Q49157119-9B73BD2D-7DAC-44EE-96DA-C5790360D302 Q50655914-9C64F8B4-A2AA-4C8D-B553-39B3A37719D2 Q53689882-C6A5B910-29BD-4FB0-9DE8-FBFBDAB4C196

P2860

Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study

http://www.wikidata.org/entity/Q35107521

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cilostazol add-on therapy in p ...... nepezil: a retrospective study

@ast

Cilostazol add-on therapy in p ...... nepezil: a retrospective study

@en

type

label

Cilostazol add-on therapy in p ...... nepezil: a retrospective study

@ast

Cilostazol add-on therapy in p ...... nepezil: a retrospective study

@en

prefLabel

Cilostazol add-on therapy in p ...... nepezil: a retrospective study

@ast

Cilostazol add-on therapy in p ...... nepezil: a retrospective study

@en

P1433

Q35107521-CE7285EE-CAD7-4EA1-BA2E-38435AD1ACB2

P1476

Q35107521-92B0229F-7B2A-4552-AD93-22B381D28D1E

P2093

Q35107521-49BFC8B7-905F-4A21-8794-BCB60A479DE7

Q35107521-4FD81F08-DEA0-4C02-865E-00D918D2521A

Q35107521-6FE6E1BD-F319-4170-835B-0741770C7242

Q35107521-9967B067-B973-4636-8D58-EFBF2F2BF4AB

Q35107521-9E47B254-CD48-40D5-B0E9-3E707FD93E1F

Q35107521-ADC222C9-9E13-4B90-827B-51058230355F

Q35107521-B71BFE89-FDBD-4A77-8AB8-68C54CE8E39A

Q35107521-F3A28C2E-A808-4BFB-A061-E33A4296137F

P2860

Q35107521-09324E75-C956-4E91-9DD3-DE1DA394CCEC

Q35107521-0C5BCEA3-2475-42BB-9F1C-18B5CCFEDC08

Q35107521-0FE9E91E-9F63-498A-835B-47A4AF25BEE0

Q35107521-476A09F8-6FC0-4AC8-A84A-53D9ECC45123

Q35107521-624461FC-CA44-4111-967D-E3B547CA7210

Q35107521-7929C8DD-D6DF-4671-BC8E-1EB196995E2F

Q35107521-889FD445-2926-44FB-82E6-D06E2CB0956A

Q35107521-9B178101-7663-4BFA-B0E4-AEFB94700B9D

Q35107521-A178024A-E950-4D75-A609-4A58A6B4B174

Q35107521-A80764F6-9328-4C58-82AF-0FD73D798A96

P304

Q35107521-4B649E1A-2BDA-4865-B3D5-BB390241BD27

P31

Q35107521-7DA7739A-7033-41B5-8A0F-085049B503B4

P356

Q35107521-2B6034AC-11B8-4CED-847D-B9CD6F7DE53E

P407

Q35107521-CB41B60A-C8F5-43A3-A392-7D933DDD3140

P433

Q35107521-F29D3E68-2C2B-42D4-8B40-36F8D8D8C200

P478

Q35107521-8BE534EB-471C-4561-95ED-77399B17BC24

P50

Q35107521-A051E2A1-8FD2-4334-80A9-62F4F70E8CA2

Q35107521-EF4BBAD8-8659-475F-8D56-2BBDE432EE3D

Q35107521-F975251F-08C7-4ED0-9BD8-C7109EFB2F8A

P577

Q35107521-FF825389-CA72-419D-BF9E-DAC86FA08A49

P5875

Q35107521-D999AA62-7501-4BA7-AF78-87E45F0305E0

P698

Q35107521-F817B186-15D9-43E7-A42C-6062D02632A5

P932

Q35107521-F5C12131-F0F0-4D8F-BCE8-205EF276BB92

P356

JOURNAL.PONE.0089516

P1433

P1476

Cilostazol add-on therapy in p ...... nepezil: a retrospective study

@en

P2093

Akihiko Taguchi

http://www.w3.org/2001/XMLSchema#string

Madoka Nishino

http://www.w3.org/2001/XMLSchema#string

Masahiro Okada

http://www.w3.org/2001/XMLSchema#string

Satoshi Saito

http://www.w3.org/2001/XMLSchema#string

Yorito Hattori

http://www.w3.org/2001/XMLSchema#string

Yu Takata

http://www.w3.org/2001/XMLSchema#string

Yukako Takahashi

http://www.w3.org/2001/XMLSchema#string

Yukiko Kasahara

http://www.w3.org/2001/XMLSchema#string

P2860

Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype.

Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

Lymphatic drainage of the brain and the pathophysiology of neurological disease.

Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.

Does vascular pathology contribute to Alzheimer changes?

Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation.

Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis.

Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice.

P304

e89516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0089516

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260448156

http://www.w3.org/2001/XMLSchema#string

P698

24586841

http://www.w3.org/2001/XMLSchema#string

P932

3935872

http://www.w3.org/2001/XMLSchema#string